Clinical applications of anticancer drugs targeted to topoisomerase II

Biochimica et Biophysica Acta - Gene Structure and Expression

Volumn 1400, Issue 1-3, 1998, Pages 173-184

  Hande, Kenneth R ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Anthracyclines; Cancer; Chemotherapy; Drug; Epipodophyllotoxins; Topoisomerase II

Indexed keywords

ANTHRACYCLINE ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; DAUNORUBICIN; DNA TOPOISOMERASE; DOXORUBICIN; EPIRUBICIN; ETOPOFOS; ETOPOSIDE; IDARUBICIN; MITOXANTRONE; TENIPOSIDE;

ANTINEOPLASTIC ACTIVITY; CANCER CHEMOTHERAPY; CELL KILLING; DOSE RESPONSE; DRUG DETERMINATION; DRUG EFFICACY; DRUG TARGETING; ENZYME INHIBITION; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; DNA TOPOISOMERASES, TYPE II; ENZYME INHIBITORS; HUMANS; MITOXANTRONE; MOLECULAR STRUCTURE; PODOPHYLLOTOXIN;

EID: 0032190407     PISSN: 01674781     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0167-4781(98)00134-1     Document Type: Review

References (64)

1. V.T. DeVita, Principles of cancer management: chemotherapy, in: V.T DeVita, S. Hellman, S.A. Rosenberg (Eds.), Cancer: Principles and Practice of Oncology, Lippincott-Raven, Philadelphia, PA, 1997, pp. 333-348.
2. Beck W.T., Danks M.K., Wolverton J.S., et al. Resistance of mammalian tumor cells to inhibitors of DNA topoisomerase II. Adv. Pharmacol. 29B:1994;145-169.
3. Endicott J.A., Ling V. The biochemistry of p-glycoprotein mediated multidrug resistance. Annu. Rev. Biochem. 58:1989;137-171.
4. Tewey K.M., Rowe T.C., Yang L., et al. Adriamycin-induced DNA damage mediated by mammalian DNA topoisomerase II. Science. 226:1984;446-468.
5. Bachur N.R., Yu F., Johnson R., et al. Helicase inhibition by anthracycline anticancer agents. Mol. Pharmacol. 41:1992;993-998.
6. Myers C.E., McGuire W.P., Liss R.H., et al. Adriamycin: the role of lipid peroxidation in cardiac toxicity and tumor response. Science. 197:1977;165-169.
7. Minofti G. Adriamycin-dependent release of iron from microsomal membranes. Arch. Biochem. Biophys. 268:1989;398-403.
8. Hortobagyi G.N. Anthracyclines in the treatment of cancer. An overview. Drugs. 54:(Suppl.):1997;1-7.
9. Urba W.J., Longo D.L. Hodgkin's disease. New Engl. J. Med. 326:1992;678-687.
10. Fisher R.I., Gaynor E.R., Dahlberg S., et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimes for advanced non-Hodgkin's lymphoma. New Engl. J. Med. 328:1993;1602-1606.
11. J.R. Harris, M. Morrow, L. Norton, Malignant tumors of the breast, in: V.T. DeVita, S. Hellman, S.A. Rosenberg (Eds.), Cancer: Principles and Practice of Oncology, Lippincott-Raven, Philadelphia, PA, 1997, pp. 1557-1616.
12. Santoro A., Tursz T., Mouridsen H., et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft-tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer, Soft-Tissue and Bone Group. J. Clin. Oncol. 13:1995;1537-1545.
13. Goebel F.D., Goldstein D., Goos M., et al. Efficacy and safety of stealth liposomal doxorubicin in AIDS-related Kaposi's sarcoma. The International SL-Dox Study Group. Br. J. Cancer. 73:1996;989-994.
14. Young R.C., Ozols R.F., Myers C.E. The anthracycline antineoplastic drugs. New Engl. J. Med. 305:1981;139-153.
15. J.H. Doroshow, Anthracyclines and anthracendiones, in: B.A. Chabner, D.L. Longo (Eds.), Cancer Chemotherapy and Biotherapy: Principles and Practice, Lippincott-Raven, Philadelphia, PA, 1996, pp. 409-434.
16. Shan K., Lincott A.M., Young J.B. Anthracycline-induced cardiotoxicity. Ann. Intern. Med. 125:1996;47-58.
17. Steinherz L.J., Steinherz P.G., Tan C.D., et al. Cardiac toxicity 4 to 20 years after completing anthracycline therapy. J. Am. Med. Assoc. 266:1991;1672-1677.
18. Swain S.M., Whaley F.S., Gerber M.D., et al. Cardioprotection with dexrazoxane for doxorubicin-containing therapy in advanced breast cancer. J. Clin. Oncol. 15:1992;1318-1332.
19. Devine S.M., Larson R.A. Acute leukemia in adults; recent developments in diagnosis and treatment. Ca Cancer J. Clin. 44:1994;326-352.
20. Von Hoff D.D., Rosencweig M., Slavik M. Adv. Pharmacol. Chemother. 15:1978;1-50.
21. Berman E. A review of idarubicin in acute leukemia. Oncology. 7:1993;91-98.
22. Feig S.A., Ames M.M., Sather H.N., et al. Comparison of idarubicin to daunorubicin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group. Med. Ped. Oncol. 27:1996;505-514.
23. Lasota W.S., deValeriola D.L., Piccart M.J. Potential role of oral anthracyclines in older patients with cancer. Drugs Aging. 4:1994;393-402.
24. Schleyer E., Kuhn S., Ruhrs H., et al. Oral idarubicin pharmacokinetics. Correlation of trough level with idarubicin area under curve. Leukemia. 11:(Suppl.):1997;15-21.
25. Robert J. Epirubicin. Clinical pharmacology and dose-effect relationship. Drugs. 45:(Suppl. 2):1993;20-30.
26. Bonadonna G., Gianne L., Santoro A., et al. Drugs ten years later: epirubicin. Ann. Oncol. 4:1993;359-369.
27. Faulds D., Balfour J.A., Chrisp P., Langtry H.D. Mitoxantrone: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the chemotherapy of cancer. Drugs. 41:1991;400-449.
28. Benjamin R.S. Rationale for the use of mitoxantrone in the older patient: cardiac toxicity. Semin. Oncol. 22:(Suppl. 1):1995;11-13.
29. Cowan J.D., Neidhardt J., McClure S., et al. Randomized trial of doxorubicin, bisantrene and mitoxantrone in advanced breast cancer: a Southwest Oncology Group study. J. Natl. Cancer lnst. 83:1991;1077-1084.
30. Stewart D.J., Evans W.K., Shepherd F.A., et al. Cyclophosphamide and fluorouracil combined with mitroxantrone versus doxorubicin for breast cancer: superiority of doxorubin. J. Clin. Oncol. 15:1997;1897-1905.
31. Tannock I.F., Osaba D., Stockler M.R., et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative endpoints. J. Clin. Oncol. 14:1996;1756-1764.
32. Posner L.E., Dukart G., Goldberg J., et al. Mitoxantrone: an overview of safety and toxicity. Invest. New Drugs. 3:1985;123-132.
33. Stahelin H.F., vonWartburg A. The chemical and biological route from podophyllotoxin glucoside to etoposide: ninth Cain Memorial award lecture. Cancer Res. 51:1991;5-15.
34. Radice P.A., Bunn P.A., Ihde D.C. Therapeutic trials with VP-16-213 and VM-26: active agents in small cell lung cancer, non-Hodgkin's lymphoma, and other malignancies. Cancer Treat. Rep. 63:1979;1231-1239.
35. Chen G.L., Yang L., Rowe T.C., et al. Non-interculative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J. Biol. Chem. 259:1984;13560-13566.
36. Minocha A., Long B. Inhibition of the DNA catenation activity of type II topoisomerase II by VP-16-213 and VM26. Biochem. Biophys. Res. Commun. 122:1984;165-170.
37. Ross W., Rowe T., Glisson B., et al. Role of topoisomerase II in mediating epipodophyllotoxin-induced DNA damage. Cancer Res. 44:1984;5857-5860.
38. O'Dwyer P.J., Leyland-Jones B., Alonso M.T., et al. Etoposide (VP-16-213). Current status of an active anticancer drug. New Engl. J. Med. 312:1985;692-700.
39. Belani C.P., Doyle L.A., Aisner J. Etoposide: current status and future prospectives in the management of malignant neoplasms. Cancer Chemother. Pharmacol. 34:(Suppl.):1994;118-126.
40. Armitage J.O. Bone marrow transplantation. New Engl. J. Med. 330:1994;827-838.
41. Blume K.G., Long G.D., Negrin R.S., et al. Role of etoposide in preparatory regimens for patients with leukemia or lymphoma undergoing allogeneic bone marrow transplantation. Bone Marrow Transplant. 14:(Suppl.):1994;9-10.
42. lhde D.C. Chemotherapy of lung cancer. New Engl. J. Med. 327:1992;1434-1441.
43. Richie J.P. Detection and treatment of testicular cancer. Ca Cancer J. Clin. 43:1993;151-175.
44. Fox M.E., Smith P.J. Long term inhibition of DNA synthesis and the persistence of trapped topoisomerase II complexes in determining the toxicity of the antitumor DNA intercalators MAMSA and mitoxantrone. Cancer Res. 50:1990;5813-5818.
45. Slevin M.L., Clark P.I., Joel S.P., et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small cell lung cancer. J. Clin. Oncol. 7:1989;1333-1340.
46. Hande K.R. The importance of drug scheduling in cancer chemotherapy: etoposide as an example. Stem Cells. 14:1996;18-24.
47. Hande K.R., Krozely M.G., Greco F.A., et al. Bioavailability of low-dose etoposide. J. Clin. Oncol. 11:1993;374-377.
48. Girling D.J. Comparison of oral etoposide and standard intravenous multidrug chemotherapy form small cell lung cancer: a stopped multicenter randomized trial. Lancet. 348:1996;563-566.
49. Hande K.R. Etoposide pharmacology. Semin. Oncol. 195:1992;3-9.
50. Budman D.R., Igwemezie L.N., Behr J., et al. Phase I evaluation of a water-soluble etoposide prodrug, etoposide phosphate, given as a 5-minute infusion on days 1, 3 and 5 in patients with solid tumors. J. Clin. Oncol. 12:1994;1902-1909.
51. Thompson D.S., Greco F.A., Miller A.A., et al. A phase I trial of etoposide phosphate administered as a daily 30-minute infusion for 5 days. Clin. Pharmacol. Ther. 57:1995;499-507.
52. deJong R.S., Slijifer E.A., Uges D.R., et al. Conversion of the prodrug etoposide phosphate to etoposide in gastric juice and bile. Br. J. Cancer. 76:1997;1480-1483.
53. deJong R.S., Mulder N.H., Uges D.R., et al. Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide. Br. J. Cancer. 75:1997;1660-1666.
54. Pui C.H., Ribeiro R.C., Hancock M.L., et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. New Engl. J. Med. 325:1991;1682-1687.
55. Nichols C.R., Breeded E.S., Loehrer P.J., et al. Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols. J. Natl. Cancer lnst. 85:1993;36-40.
56. Stine K.C., Salyors R.L., Sawyer J.R., Becton D.L. Secondary acute myelogenous leukemia following safe exposure to etoposide. J. Clin. Oncol. 15:1997;1583-1586.
57. Rivera G.K., Pui C.H., Santana V.M., et al. Epipodophyllotoxins in the treatment of childhood cancers. Cancer Chemother. Pharmacol. 34:(Suppl.):1994;89-95.
58. Muggia F.M. Teniposide: overview of its therapeutic potential in adult cancers. Cancer Chemother. Pharmacol. 34:(Suppl.):1994;127-133.
59. Gorzea P.N., Crowley J.J., Canfield V.A., et al. Teniposide single drug treatment for patients with extensive small cell lung cancer: a Phase II study of the Southwest Oncology Group. Cancer. 80:1997;1029-1033.
60. Baker D.K., Reilling M.V., Pui C.H., et al. Increased teniposide clearance with concomitant anticonvulsant therapy. J. Clin. Oncol. 10:1992;311-315.
61. Weiss R.B. Hypersensitivity reactions. Semin. Oncol. 19:1992;458-477.
62. Y. Pommier, M.R. Fesen, F. Goldwasser, Topoisomerase II inhibitors: the epipodophyllotoxins, m-AMSA, and the ellipticine derivatives, in: B.A. Chabner, D.L. Longo (Eds.), Cancer Chemotherapy and Biotherapy: Principles and Practice, Lippincott-Raven, Philadelphia, PA, 1996, pp. 435-461.
63. Sinha B.K. Topoisomerase inhibitors: a review of their therapeutic potential in cancer. Drugs. 49:1995;11-19.
64. Nitiss J.L., Beck W.T. Antitopoisomerase drug action and resistance. Eur. J. Cancer. 32A:1996;958-966.